Does the M184V resistance mutation in reverse transcriptase reduce HIV transmission?

被引：2
|
作者：
Turner, D. [1 ]
机构：
[1] Tel Aviv Univ, Sackler Fac Med, Tel Aviv Sourasky Med Ctr, Crusaid Kobler AIDS Ctr,Infect Dis Unit, IL-69978 Tel Aviv, Israel
来源：
HIV MEDICINE | 2011年 / 12卷 / 04期
关键词：
INFECTION; VARIANTS;
D O I：
10.1111/j.1468-1293.2010.00883.x
中图分类号：
R51 [传染病];
学科分类号：
100401 ;
摘要：
引用
收藏
页码：193 / 194
页数：2
相关论文
共 50 条
  • [21] Pressure of zidovudine accelerates the reversion of lamivudine resistance-conferring M184V mutation in the reverse transcriptase of human immunodeficiency virus type 1
    Diallo, K
    Oliveira, M
    Moisi, D
    Brenner, B
    Wainberg, MA
    Götte, M
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2002, 46 (07) : 2254 - 2256
  • [22] Mutations M184V and Y115F in HIV-1 Reverse Transcriptase Discriminate against "Nucleotide-competing Reverse Transcriptase Inhibitors"
    Ehteshami, Maryam
    Scarth, Brian J.
    Tchesnokov, Egor P.
    Dash, Chandravanu
    Le Grice, Stuart F. J.
    Hallenberger, Sabine
    Jochmans, Dirk
    Goette, Matthias
    JOURNAL OF BIOLOGICAL CHEMISTRY, 2008, 283 (44) : 29904 - 29911
  • [23] Reverse transcriptase mutation M184V delays the selection of thymidine-analogue mutations in children infected with subtype-C HIV-1
    Averbuch, D
    Schapiro, JM
    Engelhard, D
    Gradstein, S
    Gottesman, G
    Kedem, E
    Einhorn, M
    Grisaru-Soen, G
    Ofir, M
    Milguir, F
    Rudich, H
    Ram, D
    Grossman, Z
    ANTIVIRAL THERAPY, 2004, 9 (04) : U114 - U115
  • [24] Epidemiological and Biological Evidence for a Compensatory Effect of Connection Domain Mutation N348I on M184V in HIV-1 Reverse Transcriptase
    von Wyl, Viktor
    Ehteshami, Maryam
    Symons, Jori
    Buergisser, Philippe
    Nijhuis, Monique
    Demeter, Lisa M.
    Yerly, Sabine
    Boeni, Juerg
    Klimkait, Thomas
    Schuurman, Rob
    Ledergerber, Bruno
    Goette, Matthias
    Guenthard, Huldrych F.
    JOURNAL OF INFECTIOUS DISEASES, 2010, 201 (07): : 1054 - 1062
  • [25] Increased detection of the HIV-1 reverse transcriptase M184V mutation using mutation-specific minority assays in a UK surveillance study suggests evidence of unrecognized transmitted drug resistance
    Buckton, A. J.
    Prabhu, D.
    Motamed, C.
    Harris, R. J.
    Hill, C.
    Murphy, G.
    Parry, J. V.
    Johnson, J. A.
    Lowndes, C. M.
    Gill, N.
    Pillay, D.
    Cane, P. A.
    HIV MEDICINE, 2011, 12 (04) : 250 - 254
  • [26] Should the M184V mutation in RT be maintained as a component of HIV treatment strategies?
    Wainberg, MA
    Gotte, M
    AIDS, 2000, 14 : S33 - S33
  • [27] Kinetics and chain termination studies performed with recombinant mutated M184V and K65R HIV reverse transcriptase
    Wainberg, MA
    Quan, Y
    Gu, Z
    Li, Z
    JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES AND HUMAN RETROVIROLOGY, 1995, 10 : 5 - 5
  • [28] EntecavirSelection of M184V gene mutation: case report
    Reactions Weekly, 2019, 1778 (1) : 193 - 193
  • [29] Exquisite specificity of CTL response to the M184V mutation
    Pacheco, Y.
    Allavena, C.
    Guilloux, Y.
    Ferre, V.
    Raffi, F.
    McIlroy, D.
    RETROVIROLOGY, 2009, 6
  • [30] New resistance mutations to nucleoside reverse transcriptase inhibitors at codon 184 of HIV-1 reverse transcriptase (M184L and M184T)
    Pouga, Lydia
    Santoro, Maria Mercedes
    Charpentier, Charlotte
    Di Carlo, Domenico
    Romeo, Isabella
    Artese, Anna
    Alcaro, Stefano
    Antinori, Andrea
    Wirden, Marc
    Perno, Carlo Federico
    Ambrosio, Francesca Alessandra
    Calvez, Vincent
    Descamps, Diane
    Marcelin, Anne-Genevieve
    Ceccherini-Silberstein, Francesca
    Lambert-Niclot, Sidonie
    CHEMICAL BIOLOGY & DRUG DESIGN, 2019, 93 (01) : 50 - 59
12345